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1. Introduction  
Sarcoidosis is a multi-systemic inflammatory disorder of unknown etiology. It is classified 
as an acquired systemic granulomatous disease. Because of the fact that sarcoidosis affects 
multiple tissues and organs it is characterized by many potential signs and symptoms, as 
well as by the presence of noncaseating granulomas in the organs involved. Although 
orofacial sarcoidosis is relatively rare, it may however, present in the oral and maxillofacial 
region. The respiratory system is the most commonly affected system, with approximately 
90% of patients presenting pulmonary findings during the course of their disease. 
Cutaneous manifestations occur in around 25% of cases and are more common in chronic 
cases. Head and neck lesions of sarcoidosis are manifested in 10 to 15% of patients (Samtsov, 
1992; Newman et al., 1997; Suresh & Radfar, 2005).  
In the maxillofacial region the salivary glands may be involved, while sometimes, 
xerostomia and bilateral parotid swelling may be seen (Piattelli et al., 1998; Batal et al., 1999). 
Lesions occurring in the soft tissues of the oral cavity and/or in the jaws are rare. Orofacial 
granulomatosis (OFG) is a granulomatous disease. This clinicopathological entity describes 
patients with oral lesions characterized by persistent and/or recurrent labial enlargement, 
ulcers, and a variety of other orofacial features, which on biopsy have lymphedema and 
noncaseating granulomas. The cause is idiopathic but appears to represent an abnormal 
immune reaction. This may be a manifestation of Crohn’s disease (CD) since some patients 
with oral lesions develop typical bowel symptoms of CD in ensuing months to years; tooth 
associated infections, viruses, food or contact allergies have been implicated in causing OFG. 
Sarcoidosis has also been implicated in causing OFG. Clinical features of OFG are highly 
variable and sometimes so insidious that signs and symptoms are frequently not severe 
enough to cause alarm. The lips are most commonly involved and demonstrate a nontender, 
persistent swelling. Because of the relatively nonspecific clinical findings associated with 
granulomatous diseases, a microscopic diagnosis of granulomatous inflammation per se 
often presents a diagnostic dilemma (Shams et al., 2007). 
2. Etiology 
The cause of sarcoidosis is idiopathic but appears to represent an abnormal immune reaction. 
OFG may be a manifestation of Crohn’s disease (CD) since some patients with oral lesions 
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develop typical bowel symptoms of CD in ensuing months to years; tooth associated 
infections, viruses, food or contact allergies have been implicated in causing OFG. Sarcoidosis 
has also been implicated in causing OFG. Although the etiology of sarcoidosis is unknown, 
many factors may be accused in the pathogenesis of this disease.  Implicated causative factors 
are: infections (fungal, viral, bacterial), genetic predisposition, environmental factors and 
miscellaneous factors (DiAlberti et al., 1992 ; Mendelsohn et al., 1992 ; Rybicki et al., 
1997 ; Armstrong et al.,2004). The specific tests for fungal (mycology tests for Candida spp-
cultivation in SDA and CHROMAgar Candida), viral (Abs to HIV, EBV, CMV) and bacterial 
(for mycobacterium-skin test and AFB) infections may also be investigated. 
3. Presentation 
3.1 General findings 
The respiratory system is the most commonly affected system in sarcoidosis, with 
approximately 90% of patients presenting pulmonary findings during the course of their 
disease. Cutaneous manifestations occur in around 25% of cases and are more common in 
chronic cases. Head and neck lesions of sarcoidosis are manifested in 10 to 15% of patients 
(Armstrong et al., 2004).  
3.2 Oral and maxillofacial involvement  
In the maxillofacial region the clinical features of OFG are highly variable and sometimes so 
insidious that signs and symptoms are frequently not severe enough to cause alarm. The lips 
are most commonly involved and demonstrate a nontender, persistent swelling (Fig. 1). 
Salivary glands may be involved and xerostomia and bilateral parotid swelling may be seen. 
Lesions occurring in the soft tissues of the oral cavity and/or in the jaws are rare. Orofacial 
granulomatosis (OFG) is a granulomatous disease. This clinicopathological entity describes 
patients with oral lesions characterized by persistent and/or recurrent labial enlargement, 
ulcers, and a variety of other orofacial features, which on biopsy have lymphedema and 
noncaseating granulomas (DiAlberti et al., 1992; Mendelsohn et al., 1992; Rybicki et al., 
1997; Armstrong et al., 2004; Shams et al., 2007).  
Oral involvement generally appears in patients with chronic multisystem sarcoidosis and 
seldom occurs in the acute stage. The oral lesions may be solitary, multiple or part of a 
generalized disease. In some cases, oral involvement is the first or only, manifestation of the 
disease and appears as a nontender well-circumscribed brownish red or violeceous swelling, 
as papules, or as submucosal nodules that can occasionally either show superficial ulceration 
or be symptomatic. Gingival involvement presents as red gingival enlargement (DiAlberti et 
al., 1992; Mendelsohn et al., 1992; Rybicki et al., 1997; Armstrong et al., 2004; Shams et al., 
2007). In some cases the lesions are multifocal, including the lips, the gingiva and the hard 
palate. The clinical signs (red-violet nodular mass in the middle of the palate, and the 
erythematous and hyperplastic gingival in the upper incisor area) may be seen. Alternatively, 
oral sarcoidosis may be asymptomatic or mildly symptomatic with minimal discomfort during 
eating or drinking, especially if the lesions involve the tongue (Mendelsohn et al., 1992). 
4. Diagnosis 
In most cases of oral involvement, sarcoidosis is diagnosed before the oral manifestations 
become apparent. Occasionally, oral involvement is the first or only manifestation of the 
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disease. The diagnosis of sarcoidosis is established when clinical features are supported by 
histopathological evidence of typical non-caseating epithelioid granulomas and other 
laboratory tests (Samtsov, 1992; Newman et al., 1997; Suresh & Radfar, 2005).  
4.1 Differential diagnosis 
The differential diagnosis of oral soft tissue lesions must consider other granulomatous 
conditions, such as infections (tuberculosis, leprosy, tertiary syphilis, systemic mycoses, and 
cat-scratch disease), Crohn's disease, Melkersson-Rosenthal syndrome (including Mieschers 
cheilitis or cheilitis granulomatosa), Wegener's granulomatosis, foreign body reactions and 
hairy cell leukaemia (Rybicki et al., 1998). 
Patients with CD may present to the clinician with GI symptoms attributed to the disease or 
non-specific lesions in the oral cavity, nose, or larynx. Some OFG patients have both 
histopathological and immunopathological features that resemble those observed in CD 
patients.   Some of these clinical manifestations have been found to be consistent with CD, 
but most have not (Shams et al., 2007).  Often an extensive clinical, microscopic, and 
laboratory evaluation may be required to identify the source of the granulomatous 
inflammation (Piattelli et al., 1998).  
4.2 Evaluation tests 
As stated above, clinical microscopic, and laboratory evaluation together may be required to 
identify the source of the granulomatous inflammation. Negative endoscopy of the GI tract, 
normal ESR, normal serum albumin, Ca, folate and iron levels will rule out CD. 
With regard to sarcoidosis, a normal CXR and ACE level would make sarcoidosis unlikely. 
Chronic granulomatous disease is ruled out by using the neutrophil nitroblue tetrazolium 
reduction test (DiAlberti et al., 1992; Mendelsohn et al., 1992; Rybicki et al., 1997; Armstrong 
et al., 2004; Shams et al., 2007).  
Because of the relatively nonspecific clinical findings associated with granulomatous 
diseases, a microscopic diagnosis of granulomatous inflammation per se often presents a 
diagnostic dilemma. Clinical, microscopic, and laboratory evaluation may be required to 
identify the source of the granulomatous inflammation. The serum angiotensin converting 
enzyme  (normal value: 18-55 U/L), blood calcium  (normal value: 9-11 mEq/L) and 24-hrs 
urine calcium  (normal value <180 mg) erythrocyte sedimentation rate (1-2 mm/h) should 
be assessed. Negative endoscopy of the GI tract, normal ESR, normal serum albumin, Ca, 
folate and iron levels will rule out CD. With regard to sarcoidosis, a normal CXR and ACE 
level would make sarcoidosis unlikely. Chronic granulomatous disease is ruled out by using 
the neutrophil nitroblue tetrazolium reduction test.  
Another condition that may be associated with granuloma formation is cheilitis 
granulomatosa (CG). This is a subset of OFG, which presents clinically as persistent lip 
swelling. It also is a granulomatous inflammation of unknown origin. CG may be part of the 
triad of the Melkersson-Rosenthal syndrome (MRS). Swelling of the lips along with fissured 
tongue and facial paralysis constitute this syndrome. Lesions closely resemble nodules of 
tuberculosis (TB) and the differential diagnosis is often difficult. To make the diagnosis, other 
appropriate studies (special stains for acid fast bacilli,GMS and PAS stains for fungi, cultures, 
and so forth) to exclude tubercle bacilli, fungi, foreign bodies, or other causes of the 
granulomatous condition must be done. When the histopathological findings are compatible 
with sarcoidosis, in order to confirm the diagnosis, we must proceed with laboratory tests that 
support the diagnosis for sarcoidosis ( DiAlberti et al., 1992 ; Mendelsohn et al., 1992 ; Rybicki 
et al., 1997 ; Armstrong et al.,2004; Shams et al.,2007). 
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Fig. 1. Typical swelling of the lips. 
5. Histopathology 
Histopathologically, OFG lesions closely resemble nodules of tuberculosis (TB) and the 
differential diagnosis is often difficult. To make the diagnosis other appropriate studies 
(special stains for acid fast bacilli, GMS and PAS stains for fungi, cultures, etc.) to exclude 
tubercle bacilli, fungi, foreign bodies, or other causes of the granulomatous condition 
must be done. Photomicrographs of OFG lesions (Figs.2-8) show edema, scattered and 
clustered lymphocytes in the connective tissue as well as several well-defined, 
granulomas consisting of collections of epithelioid histiocytes and multinucleated giant 
cells  (Shams et al.,2007). 
 
 
Fig. 2. Confluent noncaseating granulomatous inflammation (H&E low power view). 
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Fig. 3. Confluent noncaseating granulomatous inflammation (H&E  medium power view). 
    
 
Fig. 4. Confluent noncaseating granulomatous inflammation (H&E  high power view).  
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Fig. 5. Sarcoidosis of skin, noncaseating granulomatous inflammation  (H&E low power). 
 
 
Fig. 6. Sarcoidosis of skin, noncaseating granulomatous inflammation  (H&E low power 
view). 
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Fig. 7. Sarcoidosis   asteroid bodies and multinucleated giant cells (H&E high power view). 
 
 
Fig. 8. Sarcoidosis   asteroid bodies and multinucleated giant cells (H&E high power view). 
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6. Treatment 
Oral glucocorticoids are the first-line treatment. Other medications include cytotoxic drugs 
such as methotrexate, azathioprine, chlorambucil, cyclosporine and cyclophosphamide. 
Some authors suggest the surgical excision for treatment of oral soft tissue or jaw lesions. A 
variety of drugs have been tried in treatment of OFG including corticosteroids.  Surgery in 
these patients is usually unnecessary as treatment is primarily pharmacological. Systemic 
corticosteroids are considered the best treatment. Glucocorticoids effectively suppress the 
activated T-helper-induced  cell processes occurring at the site of disease in 50 percent of the 
patients. The usual therapy is prednisolone 1 mg/kg for 4 to 6 weeks followed by a slow 
tapering over 2 to 3 months. This is repeated if the disease again becomes active. 
Intralesional steroid injections are also an alternative treatment method that one might also 
consider.  The prognosis is generally favourable (Shams et al., 2007).    
7. Prognosis 
Oral lesions may be the first or the only sign of sarcoidosis in an otherwise healthy patient. 
Although, oral involvement of the disease is very rare and often localized, however, the 
prognosis of orofacial sarcoidosis correlates with mode of onset, initial clinical course, 
characteristics of the host and extent of the disease. However, this multisystem disorder 
may never be completely cured. Moreover, it is important to endorse a periodic follow- up 
of patients in order to evaluate the status of the patient and course of the disease. Many of 
those affected remain asymptomatic and remission sometimes occurs spontaneously (Shams 
et al., 2007).    
8. Discussion 
The nomenclature of OFG lacks specificity. Recently, a question has been posed to 
determine whether OFG is a manifestation of a separate and specific inflammatory bowel 
disease. Other authors also suggested that OFG is a descriptive term and the specific cause 
of these lesions is unknown (Shams et al., 2007). 
Some authors (Edmondstone & Wilson, 1985 ; Hills et al., 1987 ; Edmondstone,  
1988;Bardinas et al., 1989 ;Panayeas et al., 1991 ; Rybicki et al.,1997) have reported a familial, 
(i.e. among people in the same household), seasonal and occupational clustering of 
sarcoidosis, suggesting a multifactorial origin that includes genetic predisposition, 
infectious organisms and environmental exposures as probable underlying mechanisms.  
8.1 Organ involvement 
Sarcoidosis is known to affect a wide array of organs and tissues, including the lung, heart, 
liver, spleen, bones, skin, eyes, lymph nodes, parotid glands and, on occasion, the oral 
cavity(Cahn et al., 1964 ; Tilman, 1964).  The extent of the disease and its complications vary, 
ranging from mild symptoms in some patients to major incapacitation in others (Tilman, 
1964 ; Steinberg & Mueller,1994).  Many patients experience no symptoms and are identified 
incidentally. The most prominent manifestations of the disease involve the lungs, as 
evidenced clinically by the presence of dyspnea in patients. Lung volumes and diffusing 
capacity often are reduced, and chest radiographs reveal bilateral hilar lymphadenopathy, 
diffuse parenchymal infiltrates or both (Reed, 1988; Steinberg & Mueller, 1994; Quernheim, 
1998; Hong & Farish, 2000).  
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8.2 Disease course  
The pattern of onset in sarcoidosis, the site involved determines the course and prognosis of 
the disease. Skin, eyes and lymph nodes are the most frequent sites of extrapulmonary 
involvement. Cutaneous sarcoidosis has been reported to occur in 25 percent of patients, 
and it may suggest chronicity and poor prognosis (Hong & Farish, 2000).  Similarly, one of 
four patients is affected with ocular sarcoidosis with the potential for progression to 
blindness (Steinberg & Mueller, 1994 ). Cardiac sarcoidosis and neurosarcoidosis are 
uncommon, but they may lead to fatal complications such as dysrhythmias and conduction 
block, as well as seizures and encephalopathy. Other possible systemic effects include liver 
and spleen enlargement, thrombocytopenia, abnormal calcium metabolism, renal 
dysfunction, arthropathy and skeletal deformities (Hillerup, 1976; Johns, 1988 ; Reed, 1988 ; 
Steinberg & Mueller, 1994). 
8.3 Diagnosis of exclusion 
Owing to the absence of a diagnostic gold standard, sarcoidosis is a diagnosis of exclusion 
(Quernheim, 1998 ; Hong & Farish, 2000). First, the clinician establishes a compatible clinical 
picture based on symptomatology and physical and radiographic findings. Next, the clinician 
performs a biopsy of the most accessible organ, such as skin or lymph nodes, to obtain 
histologic evidence of noncaseating granulomas. These structures are composed of focal 
aggregates of lymphocytes, macrophages and multinucleated giant cells, but they are not 
unique to this disease. Therefore, it is necessary to exclude other sources of granulomatous 
inflammation, such as foreign-body implantation, tuberculosis, Crohn’s disease and deep 
fungal infections (Israel & Sones, 1964; Reed, 1988 ; Steinberg & , Mueller, 1994 ). 
8.4 Comprehensive assessment  
Clinicians confronting patients with oral granulomatosis must perform a comprehensive 
assessment of potential target organs in patients suspected of having sarcoidosis, with 
special attention paid to the lungs, heart, central nervous system (CNS), eyes, skin and 
lymph nodes. A chest radiograph and a thorough ophthalmic evaluation are required, even 
for patients without specific pulmonary or ocular complaints. Baseline laboratory tests 
include complete blood cell counts, erythrocyte sedimentation rate, liver and renal function 
tests, serum calcium and SACE levels, pulmonary function tests, electrocardiography and 
tuberculin testing.  Periodic follow-up is essential for the clinician to evaluate the 
progression of the disease and to detect new organ involvement (Reed, 1988; Steinberg & , 
Mueller, 1994 ; Rybicki et al.,1996; DiAlberti et al.,1997 ; Rybicki et al.,1998).  
8.5 Laboratory markers 
The SACE level has been studied extensively as a laboratory marker in sarcoidosis. Secretion 
of ACE by granuloma-forming epithelioid cells results in high serum levels in 80 to 90 
percent of patients with sarcoidosis. However, because of the lack of specificity, an elevated 
SACE level is only suggestive of, rather than diagnostic for, sarcoidosis. The reported false-
positive and false-negative rates for the SACE level as a laboratory marker of sarcoidosis are 
10 and 40 percent, respectively. (Schultz et al., 1979 ; Chesnutt & Enigmas, 1995 ; Shah et al., 
1997 ; Rybicki et al.,1998)   
8.6 Pattern of onset 
The pattern of onset in sarcoidosis determines the course and prognosis of the disease, as 
well as the patient’s therapeutic response. Although spontaneous resolution is common in 
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cases of acute sarcoidosis, chronic disease often is associated with a gradual onset, a 
progressive course and many potential complications. Poor prognostic indicators include 
older age at onset, black race, hypersplenism and advanced pulmonary involvement. It is 
uncommon for patients to die of sarcoidosis and death often is attributed to terminal fibrosis 
of critical organs such as the lungs, heart or CNS (Steinberg & , Mueller, 1994;Mana et al., 
1994; Newman et al., 1997; Quernheim, 1998 ).  
8.7 Head and neck involvement 
Sarcoidosis typically is diagnosed before orofacial sequelae appear. Sarcoidosis may affect 
the head and neck lymph nodes, osseous and soft oral tissues, as well as the major and 
minor salivary glands.  Parotid glands are affected in 4 to 6 percent of cases of sarcoidosis, 
with a self-limiting or permanent enlargement as the outward presentation. Enlargements 
often are bilateral, asymptomatic, firm and smooth on palpation, with no changes in size 
when eating. Associated xerostomia may or may not be present. Although these clinical 
features are characteristic of Sjögren’s syndrome, occasionally they may be associated with 
sarcoidosis. A labial gland biopsy is a highly sensitive and specific diagnostic test in the 
histologic assessment of Sjögren’s syndrome, but it also can assist in the differentiation of 
Sjögren’s syndrome from sarcoidosis when clinical presentations are similar (Greenberg et 
al., 1964; Gold &, Sager, 1976; James et al., 1976; Giotaki et al., 1986;, Melsom et al., 1988; 
Drosos et al., 1999; Levy et al., 2001).  
Sarcoid lesions of the jaw bones may appear as diffuse, poorly defined radiolucencies on 
dental radiographs, and they can result in tooth mobility on clinical examination. 
Several studies have shown sarcoid infiltration of the minor salivary glands with or without 
clinical involvement of the major salivary glands. Therefore, when accessible and clinically 
involved tissues are not available, the clinician can perform a biopsy of normal-appearing 
tissue to confirm the histologic diagnosis in a patient with compatible clinical findings 
(Hughes & Gross, 1972; Tarpley et al,1972; Rasmussen & Neukirch, 1976; Nessan & Jacoway, 
1979).  
8.8 Labial minor salivary gland biopsy  
Several cases of sarcoidosis-induced parotid enlargement confirmed via biopsy of the labial 
minor salivary gland have been reported in the literature. This technique has a lower 
diagnostic yield in sarcoidosis compared with biopsies of the liver, lung, lymph node or 
parotid gland, perhaps because of the uncommon, delayed (after other clinical signs develop) 
and less intense histologic involvement of the minor salivary glands. On the other hand, this 
procedure is simple, minimally invasive and associated with significantly less morbidity than 
is a parotid gland biopsy. In addition, the tissue is readily accessible from the lower labial 
mucosa, and the clinician can perform the procedure under local anesthesia at chairside 
(Chisholm et al., 1971 ;Tannenbaum  et al.,1974 ; Siltzbach,1980 ; Marx et al., 1988).  
Owing to the complexity of disease manifestation, clinicians tailor therapy to each patient. 
Many patients experience temporary or long-term remission without medical therapy. 
Therefore, treatment often is deferred for three to 12 months to assess the overall disease 
progression. Immediate medical treatment is reserved for patients with neurological, 
cardiac, severe ocular, advanced pulmonary and disfiguring cutaneous disease, as well as 
persistent hypercalcemia (Turiaf et al., 1976 ; van Maarsseveen et al.,1982; Nagata et al., 
1999). Clinicians focus treatment on the suppression of the immune system, and 
corticosteroids are the mainstay of therapy. Topical, inhalational, intralesional or systemic 
steroids may be used to control the disease, depending on its severity. Physicians closely 
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monitor patients receiving long-term systemic steroid therapy for potential adverse effects 
of these medications. They also can consider steroid-sparing immunosuppressive agents for 
patients with critical organ involvement that is poorly controlled with systemic steroid 
therapy. Implanted cardiac defibrillators or heart and lung transplantation may be indicated 
for patients with cardiac and pulmonary sarcoidosis in which the organs are not 
salvageable. Splenectomy may be necessary to treat sarcoidosis-induced splenomegaly 
associated with a risk of rupture (Russo & Millikan,1994; Baughman,1997 ; Judson, 1998 ; 
Crystal, 1998 ; Pietinalho et al.,1999). 
8.9 Dental considerations 
Dentists need to consider a number of issues regarding the dental care of patients with 
sarcoidosis. Sarcoid lesions of the jaw bones may appear as diffuse, poorly defined 
radiolucencies on dental radiographs, and they can result in tooth mobility on clinical 
examination. Approximately 1 to 6 percent of patients with sarcoidosis may have an 
obstruction of the nasal passages or chronic sinusitis. Steroid supplementation before major 
oral surgery may be indicated for patients with adrenal suppression secondary to long-term 
steroid therapy. These patients also may be susceptible to infection and require prophylactic 
antibiotics before undergoing invasive dental procedures (Clayman, 1998). 
In addition, platelet retention associated with hypersplenism may lead to occasional 
thrombocytopenia, necessitating preoperative blood count studies. Anemia and other 
hematologic changes also may result from granulomatous infiltration of bone marrow 
(Yanardag et al.,2002). Practitioners also need to evaluate patients for leukopenia, anemia, 
thrombocytopenia and oral mucositis secondary to the administration of drugs that are toxic 
to bone marrow. Clinicians should defer dental procedures performed in hospitals under 
general anesthesia until a patient’s medical status and degree of vital organ dysfunction 
have been evaluated. Sarcoid infiltration of major salivary glands and subsequent 
xerostomia predispose patients to caries, periodontal disease and candidiasis, highlighting 
the need for frequent recall appointments and aggressive preventive measures with salivary 
stimulants, topical fluoride and anti-fungal medications (Yanardag et al.,2002). 
9. Conclusion  
Orofacial granulomatosis is a generic term applied to manifestations of several diseases 
including sarcoidosis, Crohn's disease, Melkersson-Rosenthal syndrome, cheilitis 
granulomatosa of Miescher and foreign-body reactions. What bonds these diseases together 
is the presence of noncaseating granulomas. A typical clinical manifestation of orofacial 
granulomatosis is recurrent labial swellings that eventually persist (Kim & Lee, 2010; 
Martini, 2010). 
Orofacial granulomatosis (OFG) is the presence of persistent enlargement of the soft tissues 
of the oral and maxillofacial region, characterized by non-caseating granulomatous 
inflammation in the absence of diagnosable systemic Crohn's disease (CD) or sarcoidosis. 
Over 20 years have passed since OFG was first described and an extensive review of the 
literature reveals that there is no consensus whether OFG is a distinct clinical disorder or an 
initial presentation of CD or sarcoidosis. Furthermore, the precise cause of OFG is still 
unknown although several theories have been suggested including infection, genetic 
predisposition and allergy. OFG is a rare granulomatous disorder, characterized by 
persistent enlargement of the soft tissues of the oral and maxillofacial region . Recurrent 
facial swelling, with/without intraoral manifestations, is the single most common 
presentation at onset. 
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Several prior studies have suggested different treatment modalities for oral CD, ranging 
from the use of mouthwash with corticosteroids to intravenous infusions of an infliximab. 
Consistent with the findings of previous reports, a favourable outcome in our patient, using 
intralesional triamcinolone, is suggestive that this can be used as a treatment option for 
patients with CD that have oral lesions. The symptoms associated with CD usually show a 
clinical course that waxes and wanes. If patients with CD complain of symptoms associated 
with these oral lesions during the course of their disease, treatment of the oral lesions with 
intralesional triamcinolone can improve the quality of life of the patients by ameliorating 
associated disease symptoms. 
In conclusion, patients presenting with an OFG should be carefully evaluated for 
gastrointestinal signs and symptoms such as diarrhea, hematochezia and abdominal pain. 
Even in cases with no presenting gastrointestinal symptoms, intestinal disease might exist 
on closer examination, thus investigation of the GI tract is highly suggested. Intralesional 
triamcinolone injections can be successful in relieving symptoms associated with oral lesions 
in a CD patient. (Kim & Lee, 2010; Martini, 2010). 
The clinical outcome of OFG patients continues to be unpredictable. Current therapies 
remain unpredictable. Regular clinical review is indicated to identify the development of 
gastrointestinal or systemic involvement. The aim of this review was to analyze the 
developments in our understanding of the aetiology, pathogenesis and treatment protocols, 
with particular emphasis on management and outcomes of this disease.  
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develop sarcoidosis than males. The symptoms of sarcoidosis depend on the organ involved. This book deals
with the diagnosis and treatment of this mysterious disease of unknown etiology.
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